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Background: The purpose of this study was to explore the budget impact of dutasteride plus tamsulosin fixed-dose
combination (DUT + TAM FDC) versus tamsulosin monotherapy, in the treatment of patients with benign prostatic
hyperplasia (BPH) from the perspective of the Greek healthcare insurance system.
Methods: A Microsoft Excel-based model was developed to estimate the financial consequences of adopting
DUT + TAM FDC within the Greek healthcare setting. The model, compared six mutually exclusive health states in
two alternative treatment options: current standard of care and the introduction of DUT + TAM FDC in the market.
The model used clinical inputs from the CombAT study; data on resource use associated with the management of BPH
in Greece were derived from expert panel, and unit cost data were derived from official reimbursement tariffs. A payer
perspective was taken into account. As patient distribution data between public and private sectors are not available
in Greece two scenarios were investigated, considering the whole eligible population in each scenario. A 4 year time
horizon was taken into account and included treatment costs, number of transurethral resections of the prostate
(TURPs) and acute urinary retention (AUR) episodes avoided.
Results: The clinical benefit from the market adoption of DUT + TAM FDC in Greece was 1,758 TURPs and 972
episodes of AUR avoided cumulatively in a four year period. The increase in total costs from the gradual introduction
of DUT + TAM FDC to the Greek healthcare system ranges from €1.3 million in the first year to €5.8 million in the fourth
year, for the public sector, and €1.2 million to €4.0 million, for the private sector. This represents an increase of 1.91% to
7.94% for the public sector and 1.10% 3.29% in the private sector, during the 4-year time horizon.
Conclusions: Budget impact analysis (BIA) results indicated that the gradual introduction of DUT + TAM FDC, would
increase the overall budget of the disease, however providing better clinical outcomes. DUT + TAM FDC drug
acquisition cost is partly offset by the reduction in the costs associated with the treatment of the disease.
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Figure 1 Markov model structure and health states.
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Benign prostatic hyperplasia (BPH), a common benign
neoplasm in men, is a chronic condition with an age
dependent epidemiology. It is associated with progressive
lower urinary tract symptoms (LUTS) and affects 75% of
men older than 70 [1]. Although many epidemiological
clinical studies have been conducted worldwide over the
last 20 years, the prevalence of clinical BPH remains
difficult to determine. A broadly accepted clinical definition
of BPH is lacking, and thus performance of adequate
epidemiological studies is hampered [2]. A commonly
occurring condition in men with underlying BPH is
acute urinary retention (AUR). AUR is an uncomfortable
and potentially life-threatening condition characterized by
a sudden inability to urinate associated with intense
suprapubic discomfort. Medical intervention is often
required in order to relieve the severe discomfort
experienced by patients with AUR [3]. Overall, the
common clinical manifestations attributed to BPH include
LUTS, urinary tract infection, incomplete bladder
emptying, acute and chronic urinary retention, chronic
renal insufficiency, urosepsis, and hematuria [1].
Therapeutic interventions for LUTS, due to BPH, provide
sustained improvement in clinical symptoms and quality of
life (QoL), while inhibiting progression of the condi-
tion [4]. The two main pharmacological agents for
the management of BPH/LUTS are 5-alpha-reductase
inhibitors (5-ARIs) and alpha-blockers. Dutasteride is a
5-ARI and works by blocking the conversion of testosterone
to dihydrotestosterone, thus reducing cellular growth and
in turn reducing the size of the prostate [5]. Tamsulosin is
an uroselective alpha-blocker and exerts its activity by
relaxing bladder neck muscles and prostate muscle
fibres that in turn improve in urine flow rate [6].
Combination therapy was significantly superior to both
monotherapies at reducing the relative risk of BPH clinical
progression, as concluded by the Combination of
AvodartTM (dutasteride) and Tamsulosin (CombAT) study.
CombAT was a randomised, multicentre, double-blind,
parallel-group study in 4,844 men of 50 years or older with
a clinical diagnosis of BPH for the treatment of moderate
to severe BPH that spanned over 4 years [7].
The increasing use of pharmacological agents, during
the past twenty years, has transformed the management of
BPH as shown by a dramatic decrease in the use of trans-
urethral prostatectomy (TURPs), inpatient hospitalization,
length of hospital stay and an increase in the number
of outpatient visits for the condition, in the US [8].
In 2000, the direct cost of BPH treatment in the US
was estimated to be US$1.1 billion exclusive of out-
patient pharmaceuticals [8]. Another study conducted
in UK estimated the annual economic burden of BPH
ranged between £62 million and £91 million, excluding
the intangible costs [9].Recent economic evaluations have been undertaken with
a specific focus on pharmaceutical intervention related to
treatment of BPH. Specifically for the DUT+TAM FDC
vs. tamsulosin monotherapy, economic analyses have been
conducted in the UK [10], Canada [11], Spain [12], and
Scandinavia [13], where the fixed-dose combination therapy
was shown to be cost-effective compared to tamsulosin
monotherapy.
The aim of this study was to assess the budget impact
of the fixed dose combination dutasteride and tamsulosin
(DUT +TAM FDC) versus tamsulosin monotherapy for
the treatment of moderate to severe BPH in Greece.Methods
A budget impact analysis was conducted based on a
Markov decision model for the treatment of moderate to
severe BPH comparing DUT + TAM FDC combination
therapy over tamsulosin monotherapy. The model was
populated with local healthcare resource utilisation
estimates, unit costs and epidemiological data. Clinical
efficacy data was retrieved from the ComBAT study.
Univariate sensitivity was conducted by examining changes
in the prevalence of BPH, number of patients based on
prostate volume, and success rate of TURPs.Model description
The pharmacoeconomic analysis was conducted based
on a Markov decision model developed with Microsoft
Excel. Using data from the CombAT study [7] the analysis
was based on a Markov stochastic process with 6 mutually
exclusive health states iterated over 3 month cycles for a
total of 4 years (Figure 1 Markov model structure and
health states). A Markov model is a decision analytic
technique that allows simulation of disease progression
during a defined period of time, and is particularly suitable
to model medical conditions that involve uncertainty over
a long time horizon and/or recurrent events [14].
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simulated each possible clinical event and described disease
progression, were the following: ‘mild’, ‘moderate’, ‘severe’
BPH, based on IPSS symptom severity as defined in the
CombAT trial, AUR, post-surgery and death [10]. The
AUR was modelled as a temporary health state. Successful
treatment of AUR with emergency catheterization or trial
without catheter (TWOC) would return the patients to the
previous health state.
Unsuccessful treatment would lead to the post-surgery
health state with the implication of a BPH-related surgery.
The model characteristics have been based on the
Walker et al. study [10]. Although there are a number of
surgical options for BPH, the model assumed all patients
have TURP when surgery is indicated. The use of TURP
has been the gold standard for decades [15] and the
American Urological Association guidelines consider this
intervention as the benchmark for surgical therapies [16],
while the European Urological Association guidelines
report TURP as the preferred treatment for prostate sizes
ranging from 30 to 80 mL [2]. Patients undergoing TURP
enter the post-surgery health state, where they remain
until the end of the 4-year time horizon or death. A
patient can undergo up to two TURP procedures (after
failure of the first procedure or relapse).
Assumptions regarding the progression of the condition
over time and BPH events, such as AUR, surgery or death
had to be made for the model. Transition probabilities
between health states [10] were derived directly from the
CombAT study individual patient-level data [7] and the
clinical study report. Patient-level data related to the mild,
moderate and severe ‘Markov’ health states were available
from follow-up visits every 3 months and accordingly
probabilities for transitions between each of these health
states were derived. For AUR and post-surgery health
states, the three-month transition probabilities were calcu-
lated from the number of yearly events using standard
methods as described by Briggs et al. [17]. For patients who
experienced AUR, the care pathway was not reported in
the CombAT trial. thus, the model assumed that 50% of
TWOC procedures are successful based on a clinical review
by Emberton et al. [18]. Furthermore, patients who
underwent BPH-related surgery followed the care pathway
that is published in international literature [19].
The European Urology Association BPH treatment
guidelines helped inform the probability of any adverse
event associated with TURP [2]. This total probability
was applied to all patients in the post-surgery state,
regardless of the success or failure of the procedure.
Adverse events (AEs) associated with medical therapy
were based on the CombAT trial. However, since the
percentage of patients experiencing serious drug-related
AEs was <1% in all treatment arms of the CombAT trial,
these were excluded from the analysis.Overall, the model simulated and compared:
 Standard of Care (SoC): Patients are treated with
tamsulosin only, representing current standard care.
 DUT + TAM FDC: Gradual introduction of DUT +
TAM FDC therapy in the treatment of BPH, with
defined market share gains over time.
In each of the treatments compared, the health costs
allocated to each discrete state were accumulated,
through the 4-year time horizon [10].
The Markov model was designed assuming that
treatment switching only occurred at the end of each
year and that patients remained on DUT + TAM FDC
therapy upon regression to mild BPH symptoms. This is
a plausible clinical assumption as according to a study
from Toren et al. [20], preventive administration of 5-ARI
could decrease the incidence of BPH clinical progression,
which was validated during the expert panel. The model
assumed 100% compliance with pharmacotherapy and that
patients incur different resource use and costs according to
the severity of their symptoms. The patients who entered
the model had an initial urology consultation at a higher
cost. The costs described in Table 1 only applied to patients
entering the model from year two onwards, since patients
in the model in year one were assumed to have already had
their initial urologist consultation. The AUR ‘Markov’ state
was modelled as a tunnel state which occurred at mid-cycle
length and no patients were assumed to be in the AUR
state at the beginning of each cycle. Non AUR patients
were only assumed to undergo TURP procedures from the
‘moderate’ and ‘severe’ symptom severity health states. No
patients were assumed to die while undergoing treatment
for AUR; all-cause mortality was applied to patients at the
beginning of each cycle. Patients who developed AUR,
following immediate catheterization, underwent TWOC. If
this was successful, they returned to their previous
symptom severity ‘Markov’ state. The AUR state was mod-
elled in this way to reflect that successful catheterization
and TWOC had no effect on disease progression.
The post-surgery ‘Markov’ state was modeled according
to Figure 2 Post surgery pathway, with the assumption that
patients underwent only one type of BPH surgery, a TURP.
Furthermore, patients were assumed to undergo a TURP
procedure when the TWOC procedure failed. Patients
undergoing a TURP procedure entered a ‘Post surgery’
health state and followed the pathway shown in Figure 2. In
this decision diagram ‘failure’ was defined when patients did
not achieve >50% reduction in the IPSS score after surgery.
Model inputs
Patient population
A cohort of Greek male patients aged ≥50 years,
diagnosed with moderate to severe BPH, as defined by an
Table 1 Unit costs by healthcare sector
Exam/laboratory test Scenario Unit cost (€) Reference
Consultation
Cost per follow up urologist visit Public 10.00 National Organization for the Provision of Healthcare Services
(EOPYY) (www.eopyy.gov.gr) accessed 1 October 2012
Private 50.00 Average price confirmed by expert panel consensus.
Cost per serum creatinine test Public 4.05 Social Security Institution IKA* tariff (PD157/55)
Private 16.00 Biomedicine SA price (provided 1 October 2012)**
Cost per urodynamic test Public 18.99 Social Security Institution IKA tariff (PD157/55)
Private 268.50 Average price from pricelists of two major private hospitals
in Athens (‘Hygeia’ hospital and ‘Iaso’ general hospital)
Cost per flexible cystoscopy Public 4.05 Social Security Institution IKA tariff column A (PD 15766 surgical)
Private 650.00 Average price from pricelists of two major private hospitals
in Athens
(Hygeia hospital and Iatriko Athinon hospital)
Procedure
Cost of prostate related surgery without
complications
Public 1,007.00 DRG list FEK 946 -12Mar2012 (DRG B02Χ)
Private 1,000.00 DRG list FEK 946 -12Mar2012 (DRG Y05Χ)
Cost of prostate related surgery with
complications
Public 2,127.00 Average of DRGs Y05M (cost of prostate related surgery with
complications) and B02M (cost of prostate related surgery with
complications) (FEK 946 -12Mar2012).
Private 2,848.00 DRG Y05M (FEK 946–12 Mar2012)
Cost per episode of AUR (non-elective) Public 7.63 Social Security Institution IKA tariff for catheterization
(PD 157/3, 157/65 surgical)
Private 50.00 Average price confirmed by expert panel consensus
*IKA Social Security fund.
**Biomedicine SA is a leading primary healthcare services provider in Greece.
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the model in order to resemble the population char-
acteristics of the CombAT study. Due to lack of national
epidemiological data on BPH, the internationally accepted
prevalence of BPH in the aforementioned age group was
used and set at 30%, while the proportion of patients
diagnosed with moderate to severe BPH was 63%, asFigure 2 Post surgery pathway.documented in international and European studies
[21-23]. Based on the 2001 Greek population census,
the men population aged over 50 was 1,724,867 and
consequently, the estimated number of men entering
the model was set at 326,000 (=1,724,867*0,3*0,63).
The initial distribution of patients in each of the BPH
symptom health states that have entered the model
was defined by the baseline IPSS of the CombAT
trial. Specifically, 7% of patients had improved to mild
symptoms (IPSS <12) before starting treatment and
the remaining 93% of patients would be considered as
moderate to severe condition (63% and 30% moderate
and severe, respectively) [11]. The IPSS range for mild
symptoms is 0–7, moderate 8–19 and severe 20–35. The
model allowed new patients to enter based on BPH
incidence in accordance with the International Society
of Pharmacoeconomics and Outcomes Research (ISPOR)
guidelines [24].
Clinical data
The CombAT trial was a 4-year randomized double-blind
parallel group study in 4,844 men ≥50 yrs. of age with
clinically diagnosed moderate to severe BPH, IPSS ≥12,
prostate volume ≥30 ml, and serum prostate specific
antigen (PSA) 1.5–10 ng/ml [7].
Geitona et al. BMC Urology 2014, 14:78 Page 5 of 9
http://www.biomedcentral.com/1471-2490/14/78The most common aetiology of male LUTS is BPH, thus
the incidence of BPH was estimated from the incident of
recorded male LUTS in the Netherlands, according to the
Verhamme et al. study [23]. Based on this study, the
calculated incidence in men aged older than 50 years
(2,090) was divided by the number of man-years (110,321)
equalling 18.94 per 1,000 man-years.
For the overall mortality weighing, the mortality rates
were calculated from the World Health Organization
(WHO) health statistics and health information system
interim life tables [25]. The annual risk of death in 2009
was extracted for Greek men aged >50 years.
Resource utilization data
The medical resource use regarding the management of
patients with BPH in Greece was not available from
existing literature or valid national data sources, thus
this information was retrieved from a local expert panel
and use of the Delphi technique [26]. A panel of 9 clinical
experts in urology was assembled in order to collect primary
data regarding patient management patterns for BPH in the
local healthcare setting. The synthesis of the panel was
geographically representative and consisted of urologists
from academic institutions and major city hospitals in
Greece. The questions related to the medical resource use
were projected on a screen and the expert panel was asked
to enter their estimates using a handheld tele-voting system.
Consensus was achieved using the Delphi method
with up to two iterations of open discussion followed
by re-voting from the panellists. The average of the
experts’ answers was then included in the model
grouped by routine care of patients with BPH, treatment
of AUR and TURP consultations.
No Ethics Committee approval was requested for the
primary research component of the study, as the conduct
of interviews with physicians and experts’ panels are not
subject to any approval according to the Greek legislation.
Cost data
Costs used in the model are in nominal 2013 Euros and
were not discounted nor inflated, as recommended by
international guidelines for BIA [24].
Drug costs for tamsulosin and DUT + TAM FDC were
based on the retail prices (Price Bulletin 15 February
2013, ΥΥΚΑ 2013/2). Specifically DUT + TAM FDC was
priced at €30.02 and tamsulosin at €12,42 (which is
the volume-weighted average price of originator and
generics according to market share data provided by
IMS Health Greece (www.imshealth.com).
As serious drug-related AEs were <1%,% in all treatment
arms of the CombAT trial, these were excluded from the
analysis.
Costs of consultations, procedures and laboratory tests
were taken from officially published public tariffs andprivate hospitals in Athens. Hospitalization costs were
based on the DRG list from the Greek Ministry of
Health, (official government gazette March 2012 [27]).
The unit costs for the private and public sector setting
are presented in Table 1.Market data
DUT + TAM FDC has been available in Greece since
2011, thus market share data (provided by IMS Health
Greece) were used as input for the model for the first
two and a half years of the analysis.
Market uptake of DUT + TAM FDC was defined as
the percentage of the total first-line treatment BPH mar-
ket that is gained every year. In particular, DUT + TAM
FDC gained 2.0%, 4.0%, 4.5% and 11.0% of market
share in the 4-years’ time horizon used in the model.
Moreover, the percent of moderate to severe BPH
patients, who switched from SoC to DUT + TAM
FDC, at the end of every year, was set to 3.0%, 4.0%,
and 5.5%.Perspective of analysis
The study was conducted from the payer perspective,
and in particular two different scenarios were investi-
gated: the public sector scenario, which includes the
costs reimbursed by social insurance funds, and the pri-
vate sector scenario, which includes the costs incurred
by patients and private health insurance. Because
there are no published estimates of the percentages of
the respective sectors in the total healthcare setting,
these two were explored separately as two extreme
scenarios.Model outputs
The model estimated the following outputs thought the
4-year time horizon from the introduction of DUT +
TAM FDC in the Greek market. Clinical outcomes refer
to the number of TURPS or number of episodes of AUR
avoided as well as the incremental cost per AUR
avoided. Economic outputs include total costs (i.e., costs
of drug treatment, costs of consultations, costs of AUR
and costs of BPH related surgery).Results
Resource utilization
Table 2 shows the resource utilisation of BPH patients,
which the expert panel affirmed was consistent across
both the social and private healthcare setting. Patients
are treated and followed up directly by urologists for all
prostate related complication, while visits to GPs are
limited to remote areas.
Table 2 Routine care for patients with BPH
Resource use Average
results
Patients with ‘Mild’ IPSS score
Number of GP visits in first year 1.22
Number of GP visits per year 0.44
Number of urologist visits per year in subsequent years 1.11
Patients with ‘Moderate’ IPSS score
Number of urologist visits in first year 2.22
Number of GP visits per year 2
Number of urologist visits per year in subsequent years 2.39
Patients with ‘Severe’ IPSS score
Number of urologist visits in first year 2.56
Number of GP visits per year 0
Number of urologist visits per year in subsequent years 2.78
Number of flexible cystoscopies per year 0.39
Proportion of patients undergoing flexible cystoscopy 7%
Successful TURP
Number of peri-operative urologist consultations 2.67
Number of follow up urodynamic tests 0.06
Unsuccessful TURP
Number of peri-operative urologist consultations 3.89
Number of follow up urodynamic tests 0.06
Patients with total and permanent incontinence
Number of urologist visits per year 4.56
Procedures with complications
Number of follow up urologist visits 3.44
All procedures
Number of peri-operative flexible cystoscopies 1.1
Abbreviations: IPSS International Prostate Symptom Score, GP general
practitioner.
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Clinical outcomes
Table 3 presents the clinical outcomes of the gradual
introduction of DUT + TAM FDC, in the 4-year time
horizon of the model.Table 3 Clinical results
Year Tamsulosin monotherapy (SoC) Tamsulosin
introduction
TURP AUR episodes TURP
1 7,145 5,786 7,102
2 12,507 6,366 12,147
3 9,637 5,943 9,215
4 11,475 7,183 10,541
Total 40,763 25,277 39,006Cost outputs
Public sector scenario
Table 4, presents the total economic impact from the
gradual introduction of DUT + TAM FDC to the
various cost components of BPH disease managment
(i.e., consultations, surgery, AUR costs, drug costs) in
the public sector.Private sector scenario
Table 5 presents the total economic impact of gradual
introduction of DUT + TAM FDC to the various cost
components of BPH disease managment (i.e., consul-
tations, surgery, AUR costs, drug costs) in the private
sector.Sensitivity analysis
In order to assess the impact of uncertainty of various
model inputs on the results of the study, univariate
sensitivity analyses were conducted on two variables that
contributed to the cost of treatment: eligible patient
population and higher success rates of TURPs.
The prevalence of BPH was allowed to vary by ±10%
in one-way sensitivity analyses, in order to reflect the
uncertainty due to lack of local epidemiological data
(Table 6).
A separate analysis estimated the budget impact from
the introduction of DUT + TAM FDC when the eligible
population included only patients with a baseline prostate
volume > 50 mL (Table 6) which according to clinical
practice is viewed as enlarged.
Additionally the success rate of surgical procedures
in terms of symptoms improvement was allowed to
vary by +11% and +22% in order to present the variation
of clinical practice [28-30]. These adjustments are aligned
with the assumption that no surgical re-treatment would
be required after initial operation.
Sensitivity analysis results indicate that the overall
budget for the treatment of BPH increases with use of
DUT + TAM FDC compared to tamsulosin monotherapy
during the 4 year study period (Table 6), for either of the
two scenarios (private and public sector).monotherapy & gradual
of DUT + TAM FDC
Number avoided






Table 4 Cost analysis of public sector
SoC: Tamsulosin monotherapy Total budget
impact (%)Year Consultation costs (€) Surgery costs (€) AUR costs (€) Drug costs (€) Total costs (€)
1 11,497,557 8,628,675 44,144 47,577,203 67,747,579 -
2 11,527,061 15,104,305 48,573 47,785,803 74,465,743 -
3 11,260,338 11,638,737 45,344 47,734,616 70,679,036 -
4 11,412,776 13,858,461 54,803 47,798,059 73,124,100 -
Tamsulosin monotherapy & gradual introduction of DUT + TAM FDC
1 11,492,585 8,577,613 43,687 48,930,196 69,044,082 -
2 11,404,330 14,669,865 47,289 50,606,379 76,727,862 -
3 11,102,755 11,128,827 43,506 52,334,084 74,609,173 -
4 11,173,679 12,730,920 50,963 54,976,669 78,932,231 -
Budget impact
1 −4,972 −51,061 −457 1,352,994 1,296,503 1.91
2 −122,731 −434,440 −1,284 2,820,575 2,262,120 3.04
3 −157,583 −509,909 −1,838 4,599,467 3,930,137 5.56
4 −239,097 −1,127,541 −3,840 7,178,610 5,808,131 7.94
Geitona et al. BMC Urology 2014, 14:78 Page 7 of 9
http://www.biomedcentral.com/1471-2490/14/78Discussion
The present study is the first to estimate the budget
impact from the introduction of DUT + TAM FDC
therapy in the treatment of moderate to severe BPH,
in the Greek health care setting. The study estimated
that the gradual introduction of DUT + TAM FDC
would result in avoidance of 1,758 TURPs and 972
AURs, in total over the 4-year time horizon, compared
with tamsulosin monotherapy. In terms of BIA, the
study showed that the introduction of the new therapeutic
intervention would increase the disease managementTable 5 Cost analysis of private sector
Year Consultation costs (€) Surgery costs (€) AUR costs (€)
SoC: Tamsulosin monotherapy
1 49,924,365 14,706,649 289,282
2 50,090,297 25,743,665 318,303
3 48,962,652 19,836,976 297,142
4 49,630,480 23,620,258 359,129
Tamsulosin monotherapy & gradual introduction of DUT + TAM FDC
1 49,898,950 14,619,620 286,287
2 49,458,768 25,003,208 309,888
3 48,142,186 18,967,890 285,101
4 48,397,466 21,698,485 333,965
Budget impact
1 −25,415 −87,028 −2,995
2 −631,529 −740,457 −8,415
3 −820,467 −869,086 −12,042
4 −1,233,014 −1,921,773 −25,163budget by 1.9% in year one, up to 7.9% in year four
from the public sector perspective, and by 1.1% to
3.3% respectively from the private sector perspective.
The observed increase is driven from pharmaceutical
costs which are partly offset by the reduction in the
costs associated with the overall treatment of the disease.
In particular, savings associated with the use of combin-
ation therapy arise from the reduction in consultations,
surgeries and AURs. These savings are estimated at €1.13
and €1.95 million in the public and private sector scenarios,













Table 6 Sensitivity analysis of net budget impact of DUT +
TAM FDC (€)
Year 1 2 3 4
Public sector 1,296,503 2,262,120 3,930,137 5,808,131
Prevalence of BPH
20% 864,336 1,553,230 2,752,483 4,195,474
40% 1,728,671 2,971,017 5,107,791 7,420,837
Only BPV > 50 cc 537,096 1,142,338 1,886,053 2,934,517
Probability that first and second TURPs
are successful
88% 1,300,878 2,299,356 3,973,923 5,904,891
99% 1,305,243 2,336,509 4,017,601 6,001,441
Private sector 1,237,555 1,440,175 2,897,873 3,998,659
Prevalence of BPH
20% 825,037 993,147 2,031,237 2,892,582
40% 1,650,074 1,887,239 3,764,509 5,104,980
Only BPV > 50 cc 422,530 719,264 1,263,342 2,003,231
Probability that first and second
TURPs are successful
88% 1,245,058 1,504,091 2,973,305 4,165,148
99% 1,252,516 1,567,598 3,048,198 4,330,599
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estimate model inputs, due to lack of local data in
published literature. Clinical data were based on the
pivotal trial (the ComBAT study), incidence, prevalence of
BPH and LUTS [29] data were extracted from European
sources [22,23], and were subsequently confirmed by the
expert panel. Our analysis was performed with inclusion
of all patients, regardless of pre-treatment prostate volume
(326,000 men estimation). Resource utilisation data
were collected via the expert panel with the use of the
Delphi technique, while local unit cost data were collected
through publicly available sources.
Among the parameters examined in the sensitivity
analyses, prevalence data had the highest impact in the
results, due to the change of eligible patients number
that enter the model.
There are certain limitations in the current study. The
analysis was performed with a computer based model,
which raised the need for adoption of simplifications
and assumptions that may have not reflected real life
data and may have created uncertainties. However, these
uncertainties were minimized through the use of expert
opinion. Due to lack of strong supporting evidence,
such as registries or officially published sources, expert
opinions were used to gather data regarding health
resource utilization.
In addition, the lack of data on the patient distribution
between the public and private sector in Greece has not
allowed the generation of a weighted average for thetotal costs. Therefore, to overcome this limitation two
extreme scenarios of public and private sectors and
the relevant unit costs, were estimated separately. The
differences observed between the two sectors’ unit cost
data are due to the fact that public sector reimbursement
rates do not reflect real cost, as they have not been
updated since 1992 [31]. The two scenarios aimed at
providing a range within which true costs lie.
Our findings may be used to inform the development
of health policy resource allocation decisions regarding
the pharmaceutical treatment of BPH. However, further
research and additional empirical data are necessary in
order to estimate more accurately the cost of DUT +TAM
FDC, and also incorporate quality of life estimates that
these patients experience compared to the currently
administered monotherapies, in the Greek healthcare set-
ting. Especially in the environment of economic recession
that Greece is experiencing, economic evaluation studies
that would reveal the value-for-money of new therapies can
help policy decision makers rely on evidence based treat-
ments and achieve health insurance fund sustainability.
Conclusions
BIA results indicated that the gradual introduction of
DUT + TAM FDC, increases the overall budget of the
disease while providing better clinical outcomes in terms
of avoidance of 1,758 TURPs and 972 AUR episodes. These
results can be used in the decision-making process for
resource allocation purposes. Further research on patient
reported outcomes and additional economic evaluation
studies that would incorporate the incremental monetary
effect with the quality-adjusted life year that BPH patients
gain from DUT+TAM FDC, compared to the currently
administered monotherapies, would reveal the value-
for-money estimate of the fixed-dose combination therapy
in the Greek healthcare system.
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